Abstract:Background: Autocrine expression of Interleukin-6 (IL-6) contributes to cholangiocarcinoma growth.IL-6 can modulate the expression of miRNA involved in tumor growth, and can also alter the expression of DNA methyltransferase 1 (DNMT-1).Alterations in DNMT-1 can epigenetically regulate the expression of tumor suppressor genes.Thus, our aim was to evaluate the role of IL-6 dependent miRNA on modulation of DNMT-1 and tumor suppressor gene expression in cholangiocarcinoma.Methods: Mz-ChA-1, KMCH-1, TFK-1 malignant and H69 nonmalignant cholangiocytes were used.Tumor cells were stably transfected to over-express IL-6.miRNA profiling was performed using a microarray and the expression of selected mature miRNA verified using real-time PCR.Luciferase reporter constructs were used to assess direct effects of miRNA at sites on DNMT-1 3'-UTR.Precursors to miRNA were used to enhance cellular expression.miRNA target prediction was performed using PicTar and Miranda databases.DNMT-1, p16INK4A and Rassf1a expression were assessed by western blot analysis.Results: miR-148a, miR-152 and miR-301 have sequence complementarity to the 3'-UTR of DNMT-1.Relative to non-malignant H69 cells, expression of miR-148a, miR-152 and miR-301 was decreased in Mz-ChA-1 cells by 0.25 ± 0.03-fold, 0.23 ± 0.02fold, and 0.07 ± 0.01-fold.Similar changes were noted in KMCH-1 and TFK cells.Expression of both miR-148a and miR-152 was decreased in IL-6 over-expressing tumor cells compared to controls in vitro (miR-148a: 0.2 ± 0.1-fold; miR-152: 0.1 ± 0.1-fold) and in tumor cell xenografts in vivo (miR-148a: 0.6 ± 0.1-fold; miR-152: 0.6 ± 0.1-fold).There was a concomitant decrease in several methylation-sensitive tumor suppressor genes including Rassf1a, and p16INK4a.DNMT-1 was verified as a direct target for miR-148a and miR-152.miR-148a decreased DNMT-1 expression by 75 ± 2% in Mz-ChA-1 and 62 ± 9% in KMCH-1 cells, and reduced cell proliferation in both cell lines.miR-152 also reduced prolfieration and decreased DNMT-1 expression by 58 ± 6 % and 62 ± 9% in Mz-ChA-1 and KMCH-1 cells respectively.Enforced expression of either miR-148a or miR-152 also increased expression of Rassf1a and p16INK4a activation.Summary and Conclusions: We report for the first time that IL-6 can (a) regulate DNMT1 expression by modulation of microRNAs miR-148a and miR-152, and (b) alter the expression of methylation dependent tumor suppressor genes Rassf1a and p16INK4a.These studies provide a direct link between IL-6 and epigenetic regulation of oncogenic pathways and justify targeting IL-6 for the prevention or treatment of cholangiocarcinoma.

2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition Via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells

AASLD Abstracts 220-442

Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

FTY720 Inhibits Proliferation and Epithelial-Mesenchymal Transition in Cholangiocarcinoma by Inactivating STAT3 Signaling

Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.

Lfg-500, A Novel Synthetic Flavonoid, Suppresses Epithelial-Mesenchymal Transition in Human Lung Adenocarcinoma Cells by Inhibiting Nlrp3 in Inflammatory Microenvironment

Α-Hederin Inhibits Interleukin 6-Induced Epithelial-to-mesenchymal Transition Associated with Disruption of JAK2/STAT3 Signaling in Colon Cancer Cells.

IL-6 Triggers the Migration and Invasion of Oestrogen Receptor-Negative Breast Cancer Cells Via Regulation of Hippo Pathways

Targeting the ILK/YAP axis by LFG-500 blocks epithelial–mesenchymal transition and metastasis

Interleukin-6 signaling pathway in targeted therapy for cancer.

Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells

Evaluating the Potential Bioactivity of a Novel Compound ER1626.

The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells

Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.

Abstract 3425: Interleukin-27 Inhibits Epithelial Mesenchymal Transition in Lung Carcinogenesis

BML-111, the agonist of lipoxin A4, suppresses epithelial-mesenchymal transition and migration of MCF-7 cells via regulating the lipoxygenase pathway

IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment

Tetrandrine Inhibits Epithelial-Mesenchymal Transition in IL-6-Induced HCT116 Human Colorectal Cancer Cells

Gr upSM Interleukin-6 as a Therapeutic Target on Human Cancer

Anti-metastatic effect of jolkinolide B and the mechanism of activity in breast cancer MDA-MB-231 cells.

Anticancer Activity of Tubulosine through Suppression of Interleukin-6-Induced Janus Kinase 2/Signal Transducer and Activation of Transcription 3 Signaling